The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according to data presented at a major medical meeting on Sunday.
The drug, lepodisiran, reduced levels of lipoprotein(a), orLp(a), by an average of 93.9% versus placebo over six months after one or two 400 milligram doses. There were 141 patients in the combined 400 mg arm of the study, while 69 received a placebo.
No serious adverse events related to the drug were reported.
"What we have is a drug that can lower lipoprotein(a) with very infrequent administration," study author Dr. Steven Nissen, a long-time cardiologist at the Cleveland Clinic, said in an interview. Nissen presented the results at the American College of Cardiology meeting in Chicago. They were also published in the New England Journal of Medicine.
Read Full Article Here
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
- by: Julie Steenhuysen
- 2025-03-30
- Source:
Yahoo
- 04/01/2025
